Vivacta Limited, a Sittingbourne, UK-based medical diagnostics company that develops an innovative platform for point of care testing, closed a £4m financing round.
The existing shareholders, HBM BioVentures, IDInvest Partners (formerly AGF Private Equity), Spark Ventures and Viking, all participated in the round.
Vivacta’s innovative piezofilm technology platform enables the advancement of new near‐patient diagnostic products. The company has successfully developed a test for thyroid stimulating hormone (TSH), and is working on a multiple analyte cardiovascular diagnostic test for use in the emergency room and acute
care settings, where there is a need for rapid diagnosis of possible heart attack and related time‐critical medical conditions.
As stated by Dr Tim Carter, CEO of Vivacta, this fundraising will enable the company to continue to maximize the potential of its platform.